BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 25320502)

  • 1. Medical management of gastric cancer: a 2014 update.
    Elimova E; Shiozaki H; Wadhwa R; Sudo K; Chen Q; Estrella JS; Blum MA; Badgwell B; Das P; Song S; Ajani JA
    World J Gastroenterol; 2014 Oct; 20(38):13637-47. PubMed ID: 25320502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.
    Miceli R; Tomasello G; Bregni G; Di Bartolomeo M; Pietrantonio F
    World J Gastroenterol; 2014 Apr; 20(16):4516-25. PubMed ID: 24782604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advancing pharmacological treatment options for advanced gastric cancer.
    Sudo K; Yamada Y
    Expert Opin Pharmacother; 2015; 16(15):2293-305. PubMed ID: 26359224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America.
    Knight G; Earle CC; Cosby R; Coburn N; Youssef Y; Malthaner R; Wong RK;
    Gastric Cancer; 2013 Jan; 16(1):28-40. PubMed ID: 22467061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
    Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
    Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
    Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
    Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing Therapies in the Perioperative Management of Gastric Cancer.
    Khan U; Shah MA
    Curr Treat Options Oncol; 2019 May; 20(7):57. PubMed ID: 31144054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond.
    Choi AH; Kim J; Chao J
    World J Gastroenterol; 2015 Jun; 21(24):7343-8. PubMed ID: 26139980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy beyond first-line in advanced gastric cancer: An overview of the main randomized clinical trials.
    Galdy S; Cella CA; Spada F; Murgioni S; Frezza AM; Ravenda SP; Zampino MG; Fazio N
    Crit Rev Oncol Hematol; 2016 Mar; 99():1-12. PubMed ID: 26697987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.
    Slagter AE; Jansen EPM; van Laarhoven HWM; van Sandick JW; van Grieken NCT; Sikorska K; Cats A; Muller-Timmermans P; Hulshof MCCM; Boot H; Los M; Beerepoot LV; Peters FPJ; Hospers GAP; van Etten B; Hartgrink HH; van Berge Henegouwen MI; Nieuwenhuijzen GAP; van Hillegersberg R; van der Peet DL; Grabsch HI; Verheij M
    BMC Cancer; 2018 Sep; 18(1):877. PubMed ID: 30200910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant therapy for locally advanced gastric cancer.
    Aoyama T; Yoshikawa T
    Surg Today; 2017 Nov; 47(11):1295-1302. PubMed ID: 28251375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced gastric cancer: is there enough evidence to call second-line therapy standard?
    Arkenau HT; Saggese M; Lemech C
    World J Gastroenterol; 2012 Nov; 18(44):6376-8. PubMed ID: 23197882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy for advanced gastric cancer.
    Wagner AD; Unverzagt S; Grothe W; Kleber G; Grothey A; Haerting J; Fleig WE
    Cochrane Database Syst Rev; 2010 Mar; (3):CD004064. PubMed ID: 20238327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What make differences in the outcome of adjuvant treatments for resected gastric cancer?
    Nakajima T; Fujii M
    World J Gastroenterol; 2014 Sep; 20(33):11567-73. PubMed ID: 25206264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).
    Kataoka K; Tokunaga M; Mizusawa J; Machida N; Katayama H; Shitara K; Tomita T; Nakamura K; Boku N; Sano T; Terashima M; Sasako M;
    Jpn J Clin Oncol; 2015 Nov; 45(11):1082-6. PubMed ID: 26355164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.
    Ajani JA; Winter K; Okawara GS; Donohue JH; Pisters PW; Crane CH; Greskovich JF; Anne PR; Bradley JD; Willett C; Rich TA
    J Clin Oncol; 2006 Aug; 24(24):3953-8. PubMed ID: 16921048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
    Leong T; Smithers BM; Michael M; Gebski V; Boussioutas A; Miller D; Simes J; Zalcberg J; Haustermans K; Lordick F; Schuhmacher C; Swallow C; Darling G; Wong R
    BMC Cancer; 2015 Jul; 15():532. PubMed ID: 26194186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literature.
    Berardi R; Scartozzi M; Galizia E; Cascinu S
    Suppl Tumori; 2003; 2(5):S45-7. PubMed ID: 12914390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.